Peggy S McKinnon

Summary

Affiliation: Barnes-Jewish Hospital
Country: USA

Publications

  1. ncbi request reprint Cost perspectives for outpatient intravenous antimicrobial therapy
    Alan D Tice
    Outpatient Parenteral Antibiotic Therapy OPAT, Outcomes Registry, Tacoma, Washington 98402, USA
    Pharmacotherapy 22:63S-70S. 2002
  2. ncbi request reprint The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective
    Peggy S McKinnon
    Clinical Research Infectious Diseases, Barnes Jewish Hospital, St Louis, Missouri 63110, USA
    Manag Care Interface 20:23-34. 2007
  3. ncbi request reprint Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections
    Peggy S McKinnon
    Clinical Research Infectious Diseases, Barnes Jewish Hospital, St Louis, MO 63110, USA
    Ann Pharmacother 40:1017-23. 2006
  4. doi request reprint Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections
    Peggy S McKinnon
    Clinical Research Infectious Diseases, Barnes Jewish Hospital, St Louis, MO 63110, USA
    Int J Antimicrob Agents 31:345-51. 2008
  5. ncbi request reprint Early clinical experience with anidulafungin at a large tertiary care medical center
    Benjamin D Brielmaier
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, Missouri 63110, USA
    Pharmacotherapy 28:64-73. 2008
  6. doi request reprint Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever
    Heather M Arnold
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, Missouri 63110, USA
    Pharmacotherapy 29:914-23. 2009
  7. ncbi request reprint Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes
    Susan L Davis
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA
    Pharmacotherapy 27:1611-8. 2007
  8. ncbi request reprint Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
    Pharmacotherapy 27:1001-12. 2007
  9. ncbi request reprint Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices
    Meghan N Jeffres
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, MO, USA
    Chest 130:947-55. 2006
  10. ncbi request reprint An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures
    Madeline Betancourt
    College of Pharmacy, Wayne State University, Detroit, Michigan, USA
    Pharmacoeconomics 21:1331-40. 2003

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Cost perspectives for outpatient intravenous antimicrobial therapy
    Alan D Tice
    Outpatient Parenteral Antibiotic Therapy OPAT, Outcomes Registry, Tacoma, Washington 98402, USA
    Pharmacotherapy 22:63S-70S. 2002
    ..We found that the cost of outpatient therapy was substantial, although nonuniform, across payer types. Alternative outpatient therapies associated with lower risks for adverse events and lower costs should be considered...
  2. ncbi request reprint The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective
    Peggy S McKinnon
    Clinical Research Infectious Diseases, Barnes Jewish Hospital, St Louis, Missouri 63110, USA
    Manag Care Interface 20:23-34. 2007
    ..Outpatient treatment with oral linezolid was associated with significantly lower resource utilization and total medical costs compared with IV vancomycin...
  3. ncbi request reprint Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections
    Peggy S McKinnon
    Clinical Research Infectious Diseases, Barnes Jewish Hospital, St Louis, MO 63110, USA
    Ann Pharmacother 40:1017-23. 2006
    ..In clinical trials, linezolid has demonstrated higher clinical cure rates and shorter hospital duration for patients than has vancomycin for the treatment of complicated skin and soft-tissue infections (cSSTIs)...
  4. doi request reprint Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections
    Peggy S McKinnon
    Clinical Research Infectious Diseases, Barnes Jewish Hospital, St Louis, MO 63110, USA
    Int J Antimicrob Agents 31:345-51. 2008
    ..001) than patients with T>MIC of <100%. Both microbiological and clinical cure rates were suboptimal in patients receiving cefepime or ceftazidime for the treatment of serious infections if the AUIC was <250 or T>MIC was <100%...
  5. ncbi request reprint Early clinical experience with anidulafungin at a large tertiary care medical center
    Benjamin D Brielmaier
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, Missouri 63110, USA
    Pharmacotherapy 28:64-73. 2008
    ..To evaluate early clinical experience with anidulafungin...
  6. doi request reprint Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever
    Heather M Arnold
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, Missouri 63110, USA
    Pharmacotherapy 29:914-23. 2009
    ....
  7. ncbi request reprint Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes
    Susan L Davis
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA
    Pharmacotherapy 27:1611-8. 2007
    ..To assess the effect of daptomycin compared with vancomycin on the clinical and economic outcomes in patients with complicated skin and skin structure infections...
  8. ncbi request reprint Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
    Pharmacotherapy 27:1001-12. 2007
    ..Further studies are needed to determine if these drugs can better eradicate MRSA than vancomycin and remedy the adverse outcomes frequently observed with this organism...
  9. ncbi request reprint Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices
    Meghan N Jeffres
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, MO, USA
    Chest 130:947-55. 2006
    ....
  10. ncbi request reprint An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures
    Madeline Betancourt
    College of Pharmacy, Wayne State University, Detroit, Michigan, USA
    Pharmacoeconomics 21:1331-40. 2003
    ..Consequently, some institutions restrict drotrecogin alfa (activated) use to patients with severe sepsis with >/=2 organ system failures...
  11. ncbi request reprint Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model
    Nisha P Shah
    Health Economic Research and Quality of Life Evaluation Services HERQuLES, Abt Associates Inc, Cambridge MA, USA
    Curr Med Res Opin 20:779-90. 2004
    ..Univariate and multivariate sensitivity analyses were conducted to confirm the robustness of the baseline scenario...
  12. ncbi request reprint Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, CT, USA
    Chest 128:1414-22. 2005
    ..To describe outcomes associated with nosocomial bacteremic Staphylococcus aureus pneumonia (NBSAP) and to determine whether delay in adequate antimicrobial treatment is a risk factor for negative clinical and microbiological outcomes...
  13. ncbi request reprint Pharmacodynamics of cefepime in patients with Gram-negative infections
    Vincent H Tam
    The Anti Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, Wayne State University, MI, USA
    J Antimicrob Chemother 50:425-8. 2002
    ..3 x MIC. Our results support in vitro data that suggest bactericidal activity of beta-lactams is optimized at concentrations approximately 4 x MIC. These results should be validated by large prospective clinical trials...
  14. pmc Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function
    Vincent H Tam
    Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 47:1853-61. 2003
    ..Current dosing recommendations may be suboptimal for monotherapy of infections due to less susceptible pathogens (e.g., those for which MICs are > or = 4 mg/liter), particularly when CL(CR) exceeds 120 ml/min...
  15. ncbi request reprint Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital
    Gita Wasan Patel
    Department of Pharmacy, Medical Center of Plano, Plano, Texas 75075, USA
    Pharmacotherapy 27:1637-43. 2007
    ..To compare outcomes and cost for the traditional United States Food and Drug Administration-approved dosing regimen for meropenem versus an alternative dosing regimen providing similar pharmacodynamic exposure with a lower total daily dose...
  16. pmc Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus
    Thomas P Lodise
    Albany College of Pharmacy, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 51:3731-3. 2007
    ....
  17. ncbi request reprint Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients
    Susan L Davis
    Wayne State University, and Henry Ford Hospital, Detroit, MI, USA
    Ann Pharmacother 41:568-73. 2007
    ..Candidemia is a major cause of morbidity and mortality in hospitalized patients...
  18. ncbi request reprint Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia
    Thomas P Lodise
    Anti Infective Research Laboratory, Detroit Receiving Hospital and University Health Center, Detroit, MI, USA
    Clin Infect Dis 36:1418-23. 2003
    ..2 days versus 14.3 days; P=.05). These findings support the notion that delay of therapy has deleterious effects on clinical outcomes, and efforts should be made to ensure that appropriate therapy is initiated promptly...
  19. ncbi request reprint Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 52:113-22. 2005
    ..With the advent of new treatment options, the impact of MRSA will need to be revisited to determine if these therapies can remedy the increased morbidity associated with MRSA...
  20. ncbi request reprint Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus
    Susan L Davis
    Anti Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences and the School of Medicine, Wayne State University, Detroit, MI 48201, USA
    Infect Control Hosp Epidemiol 27:1025-31. 2006
    ..The objective of the present study was to characterize the epidemiology of and clinical outcomes associated with SCCmec-IV MRSA infection acquired in the healthcare setting, compared with infection caused by MRSA of other SCCmec types...
  21. ncbi request reprint Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients
    Salmaan Kanji
    College of Pharmacy, Wayne State University, Detroit, MI, USA
    Crit Care Med 31:1347-52. 2003
    ..We evaluated the effect of critical illness and concomitant gastric tube feeding on gatifloxacin bioavailability...
  22. ncbi request reprint Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 54:223-30. 2006
    ..03 and 8 microg/mL for each regimen examined. In CSF, none of the regimens achieved 50-100% T>MIC for>80% of patients for MICs>0.5 mg/L...
  23. ncbi request reprint A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone
    John F Mohr
    Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    Pharmacotherapy 25:1303-9. 2005
    ..To compare rates of blood glucose abnormalities in hospitalized patients receiving fluoroquinolones or ceftriaxone, and to describe the characteristics of patients who develop blood glucose abnormalities while receiving these agents...
  24. ncbi request reprint Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance
    Thomas P Lodise
    Anti Infective Research Laboratory, Detroit Receiving Hospital, Wayne State University, 4201 St Antoine Blvd, 1 B UHC, Detroit, MI 48201, USA
    Infect Control Hosp Epidemiol 24:655-61. 2003
    ..To identify institution-specific risk factors for MRSA bacteremia and develop an objective mechanism to estimate the probability of methicillin resistance in a given patient with Staphylococcus aureus bacteremia (SAB)...